Background: We provided a comprehensive evaluation of efficacy of available treatments for
coronavirus disease 2019 (COVID-19). Methods: We searched for candidate COVID-19 …

An updated version of this article was published on 19 September 2023. This article has
been corrected. The original version of the article and supplement (PDF) is appended to this …

Summary Background Previous Randomised controlled trials (RCT) evaluating chloroquine
and hydroxychloroquine in non-hospitalised COVID-19 patients have found no significant …

An updated version of this article was published on 19 September 2023. Description:
Strategies to manage COVID-19 in the outpatient setting continue to evolve as new data …

Objectives To update the EULAR points to consider (PtCs) on the use of immunomodulatory
therapies in COVID-19. Methods According to the EULAR standardised operating …

Introduction Drug repositioning is a strategy to identify a new therapeutic indication for
molecules that have been approved for other conditions, aiming to speed up the traditional …

Background Since the beginning of the COVID-19 pandemic, therapeutic options for treating
COVID-19 have been investigated at different stages of clinical manifestations. Considering …

Hydroxychloroquine (HCQ) was initially promoted as an oral therapy for early treatment of
coronavirus disease 2019 (COVID‐19). Conventional meta‐analyses cannot fully address …

Background During pandemics, early outpatient treatments reduce the health system
burden. Randomized controlled trials (RCTs) in COVID-19 outpatients have tested …

This COVID‐19 outpatient randomized controlled trials (RCTs) systematic review compares
hospitalization outcomes amongst four treatment classes over pandemic period, geography …